COMP <GO>
ELV vs JNJ // RSI-14 & 200D SMA MOMENTUM
Elevance Health Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ELV 7
— JNJ 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: JNJ
LAST: $420.07 (-0.46%) • MKT CAP: $91.18B
rsi-technicals
50.8
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
rsi-technicals
60.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELV VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ELV | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.40% | 67.90% | +21.50 | ELV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.70% | 25.50% | -16.80 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.8x | 18.5x | -4.70 | ELV | /valuation <GO> |
| Free Cash Flow Yield | 3.48% | 2.97% | +0.51 | ELV | /fcf-yield <GO> |
| Operating Margin | 3.60% | 34.70% | -31.10 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 2.80% | 28.50% | -25.70 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 12.50% | 6.00% | +6.50 | ELV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.68% | 0.00% | +1.68 | ELV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.17 | 5.59 | -2.42 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.20% | -0.10 | ELV | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 50.8 | 60.4 | -9.58 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 1.08 | -0.01 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 13.5x | 23.0x | -9.50 | ELV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $91.18B | $662.49B | -$571.31B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ELV REV | JNJ REV | ELV GROSS % | JNJ GROSS % | ELV FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $199.13B | $94.19B | 89.4% | 67.9% | $3.17B | $19.70B |
| FY 2024 | $177.01B | $88.82B | 88.8% | 69.1% | $4.55B | $19.84B |
| FY 2023 | $171.34B | $85.16B | 44.0% | 44.0% | $350.7M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELV // BETA 1.07
JNJ // BETA 1.08